Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency

Conditions

• XIAP Deficiency

Eligibility Criteria

Sex

MALE

Age

2 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Quercetin — DRUG
  Quercetin will be administered orally at a weight adjusted dose for a maximum total daily dose of 4000mg/day, divided twice a day. If the patient is 70 kg or more, the dose will automatically be assigned at the maximum dose of 4000mg/day. Patients will be instructed to mix quercetin with a small amount of yogurt or other preferred food for ingestion.

Study Details

The purpose of the study is to evaluate safety and tolerability of oral quercetin in reducing inflammation in male patients with XIAP deficiency. Quercetin is a naturally occurring antioxidant that has many properties including the ability to decrease inflammation in other diseases.

Key Dates

Start date

Feb 26, 2026

Status verified

Mar 2026

Primary completion

Nov 30, 2028

Completion

Jun 30, 2029

Study Design

Enrollment

12 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Quercetin
  All subjects will receive a weight adjusted dose of quercetin for a maximum total daily dose of 4000mg/day, divided twice a day.

Primary Outcome Measure

Safety of quercetin in patients with XIAP deficiency [ Time Frame: 6 months ]

Central Contacts

• Kelly McIntosh
  513-803-0460
  [email protected]
• Richard Cooper
  513-803-7450
  [email protected]

Locations (1)

Find similar trials in Cincinnati, OH